Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal vaccine GSK134612 + human papillomavirus vaccine
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The combination of **meningococcal vaccine GSK134612** and **human papillomavirus vaccine** refers to a co-administration regimen developed by GSK, primarily evaluated in adolescent populations. The meningococcal component, **GSK134612** (marketed as **Menveo**), is a quadrivalent conjugate vaccine targeting *Neisseria meningitidis* serogroups A, C, W-135, and Y, with each capsular polysaccharide conjugated to a non-toxic mutant of diphtheria toxin (CRM197). The human papillomavirus component (marketed as **Cervarix**, code **GSK580299**) is a bivalent vaccine targeting oncogenic HPV types 16 and 18, utilizing recombinant L1 capsid proteins formulated as virus-like particles (VLPs) with the **AS04** adjuvant system (aluminum hydroxide and monophosphoryl lipid A). This combination has been investigated in Phase 3 clinical trials to demonstrate that simultaneous administration maintains the safety and immunogenicity profiles of both vaccines, thereby facilitating streamlined immunization schedules for the prevention of invasive meningococcal disease and HPV-related cancers.
- Brand names
- MenveoCervarix
- Other names
- MenACWY-CRM + HPV-16/18 vaccineQuadrivalent meningococcal conjugate vaccine + Bivalent HPV vaccine
02
Targets
NeuraminidaseHPV16 (Human papillomavirus type 16)HPV18 L1NmA CPS (Neisseria meningitidis group A capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharideMenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)
Beyond the preview
Go deeper on meningococcal vaccine GSK134612 + human papillomavirus vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal vaccine GSK134612 + human papillomavirus vaccine.